Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors time their entries correctly. The following biotech stocks we profiled on our site reached 52-week highs yesterday.
*Last Closing Price refers to the stock's closing price on Sep.19, 2024.
Ticker
Published Date
Published Price
Maximum Price Since Publication
*Last Closing Price
Maximum Gain %
Edgewise Therapeutics, Inc. (EWTX)
Oct.16, 2023
$6.71
$30.00
$29.50
347%
Travere Therapeutics Inc. (TVTX)
Aug.14, 2024
$8.91
$15.23
$15.06
71%
Catalyst Pharmaceuticals Inc. (CPRX)
Feb.13, 2024
$13.32
$21.36
$21.35
60%
MannKind Corp. (MNKD)
Apr.8, 2024
$4.47
$6.92
$6.70
55%
Rockwell Medical Inc. (RMTI)
Sep.4, 2024
$3.21
$4.45
$4.14
38%
Rhythm Pharmaceuticals Inc. (RYTM)
Dec.1, 2023
$33.66
$55.64
$54.55
65%
Eton Pharmaceuticals Inc. (ETON)
Sep.8, 2023
$4.51
$6.02
$5.90
33%
Vaxcyte Inc. (PCVX)
Apr.30, 2024
$60.61
$121.06
$117.12
99%
RadNet Inc. (RDNT)
Mar.1, 2023
$23.47
$70.37
$69.64
199%
Merit Medical Systems Inc. (MMSI)
Oct.27, 2022
$62.71
$101.26
$100.23
61%
ADMA Biologics Inc. (ADMA)
Feb.15, 2024
$5.36
$19.92
$19.74
271%
Related Reading
ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In?
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.